[
  {
    "ts": null,
    "headline": "Aptiv: Proposed Spinoff Makes It A Buy",
    "summary": "Unlock value with Aptiv PLC's EDS spinoff, focusing on high-growth segments, reducing risks, and driving capital efficiency. Click to read why APTV is a Buy.",
    "url": "https://finnhub.io/api/news?id=78b46243813ec18ec7414a7e4f8e6448e6ad38d07ae705f3045827c98541fc65",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755537034,
      "headline": "Aptiv: Proposed Spinoff Makes It A Buy",
      "id": 136412501,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401320102/image_1401320102.jpg?io=getty-c-w1536",
      "related": "APTV",
      "source": "SeekingAlpha",
      "summary": "Unlock value with Aptiv PLC's EDS spinoff, focusing on high-growth segments, reducing risks, and driving capital efficiency. Click to read why APTV is a Buy.",
      "url": "https://finnhub.io/api/news?id=78b46243813ec18ec7414a7e4f8e6448e6ad38d07ae705f3045827c98541fc65"
    }
  },
  {
    "ts": null,
    "headline": "This car is the next big thing in driving — and you can invest in it right now",
    "summary": "This car is the next big thing in driving — and you can invest in it right now",
    "url": "https://finnhub.io/api/news?id=3e4ce763f67622edea07bac693c68bee40feee1f881f9b0c18fba4704aa85967",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755514020,
      "headline": "This car is the next big thing in driving — and you can invest in it right now",
      "id": 136419370,
      "image": "",
      "related": "APTV",
      "source": "MarketWatch",
      "summary": "This car is the next big thing in driving — and you can invest in it right now",
      "url": "https://finnhub.io/api/news?id=3e4ce763f67622edea07bac693c68bee40feee1f881f9b0c18fba4704aa85967"
    }
  },
  {
    "ts": null,
    "headline": "Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy",
    "summary": "ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effe",
    "url": "https://finnhub.io/api/news?id=540d856345fab1ada6841d4a848503cfd21b1b32bce129d0dbf4c5ce3adc8216",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755520200,
      "headline": "Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy",
      "id": 136409375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "APTV",
      "source": "Yahoo",
      "summary": "ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effe",
      "url": "https://finnhub.io/api/news?id=540d856345fab1ada6841d4a848503cfd21b1b32bce129d0dbf4c5ce3adc8216"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Raised the Firm’s PT on Aptiv PLC (APTV), Kept an Outperform Rating",
    "summary": "Aptiv PLC (NYSE:APTV) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 8, Oppenheimer analyst Colin Rusch raised the firm’s price target on Aptiv PLC (NYSE:APTV) from $84 to $88, while keeping an Outperform rating on the stock. The bullish sentiment follows the company’s strong second-quarter 2025 results. The […]",
    "url": "https://finnhub.io/api/news?id=b613a0f9255cce974093412a57985d007d1037adb1a57c631e45e66f6efa1991",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755490993,
      "headline": "Oppenheimer Raised the Firm’s PT on Aptiv PLC (APTV), Kept an Outperform Rating",
      "id": 136409376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "APTV",
      "source": "Yahoo",
      "summary": "Aptiv PLC (NYSE:APTV) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 8, Oppenheimer analyst Colin Rusch raised the firm’s price target on Aptiv PLC (NYSE:APTV) from $84 to $88, while keeping an Outperform rating on the stock. The bullish sentiment follows the company’s strong second-quarter 2025 results. The […]",
      "url": "https://finnhub.io/api/news?id=b613a0f9255cce974093412a57985d007d1037adb1a57c631e45e66f6efa1991"
    }
  }
]